Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions

Published:September 17, 2014DOI:


      Women with germline mutations in the cancer susceptibility genes, BRCA1 or BRCA2, associated with Hereditary Breast & Ovarian Cancer syndrome, have up to an 85% lifetime risk of breast cancer and up to a 46% lifetime risk of ovarian, tubal, and peritoneal cancers. Similarly, women with mutations in the DNA mismatch repair genes, MLH1, MSH2, MSH6, or PMS2, associated with the Lynch/Hereditary Non-Polyposis Colorectal Cancer (HNPCC) syndrome, have up to a 40–60% lifetime risk of both endometrial and colorectal cancers as well as a 9–12% lifetime risk of ovarian cancer. Mutations in other genes including TP53, PTEN, and STK11 are responsible for hereditary syndromes associated with gynecologic, breast, and other cancers. Evaluation of the likelihood of a patient having one of these gynecologic cancer predisposition syndromes enables physicians to provide individualized assessments of cancer risk, as well as the opportunity to provide tailored screening and prevention strategies such as surveillance, chemoprevention, and prophylactic surgery that may reduce the morbidity and mortality associated with these syndromes. Evaluation for the presence of a hereditary cancer syndrome is a process that includes assessment of clinical and tumor characteristics, education and counseling conducted by a provider with expertise in cancer genetics, and may include genetic testing after appropriate consent is obtained. This commentary provides guidance on identification of patients who may benefit from assessment for the presence of a hereditary breast and/or gynecologic cancer syndrome.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Gynecologic Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Garber J.E.
        • Offit K.
        Hereditary cancer predisposition syndromes.
        J Clin Oncol. 2005; 23: 276-292
        • Karlan B.Y.
        • Berchuck A.
        • Mutch D.
        The role of genetic testing for cancer susceptibility in gynecologic practice.
        Obstet Gynecol. 2007; 110: 155-167
        • Wooster R.
        • Weber B.L.
        Breast and ovarian cancer.
        N Engl J Med. 2003; 348: 2339-2347
        • Lynch H.T.
        • de la Chapelle A.
        Hereditary colorectal cancer.
        N Engl J Med. 2003; 348: 919-932
        • Miki Y.
        • et al.
        A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1.
        Science. 1994; 266: 66-71
        • Wooster R.
        • et al.
        Identification of the breast cancer susceptibility gene BRCA2.
        Nature. 1995; 378: 789-792
        • Lancaster J.M.
        • et al.
        BRCA2 mutations in primary breast and ovarian cancers.
        Nat Genet. 1996; 13: 238-240
        • Fishel R.
        • et al.
        The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer.
        Cell. 1993; 75: 1027-1038
        • Leach F.S.
        • et al.
        Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer.
        Cell. 1993; 75: 1215-1225
        • Bronner C.E.
        • et al.
        Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer.
        Nature. 1994; 368: 258-261
        • Papadopoulos N.
        • et al.
        Mutation of a mutL homolog in hereditary colon cancer.
        Science. 1994; 263: 1625-1629
        • Walsh T.
        • et al.
        Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing.
        Proc Natl Acad Sci U S A. 2011; 108: 18032-18037
        • Ford D.
        • et al.
        Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium.
        Am J Hum Genet. 1998; 62: 676-689
        • Antoniou A.
        • et al.
        Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies.
        Am J Hum Genet. 2003; 72: 1117-1130
        • King M.C.
        • Marks J.H.
        • Mandell J.B.
        • New York Breast Cancer Study Group
        Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2.
        Science. 2003; 302: 643-646
        • Barrow E.
        • Hill J.
        • Evans D.G.
        Cancer risk in Lynch syndrome.
        Fam Cancer. 2013; 12: 229-240
        • Vasen H.F.
        • et al.
        MSH2 mutation carriers are at higher risk of cancer than MLH1 mutation carriers: a study of hereditary nonpolyposis colorectal cancer families.
        J Clin Oncol. 2001; 19: 4074-4080
        • Hendriks Y.M.
        • et al.
        Cancer risk in hereditary nonpolyposis colorectal cancer due to MSH6 mutations: impact on counseling and surveillance.
        Gastroenterology. 2004; 127: 17-25
        • Plaschke J.
        • et al.
        Lower incidence of colorectal cancer and later age of disease onset in 27 families with pathogenic MSH6 germline mutations compared with families with MLH1 or MSH2 mutations: the German Hereditary Nonpolyposis Colorectal Cancer Consortium.
        J Clin Oncol. 2004; 22: 4486-4494
        • Barrow E.
        • et al.
        Colorectal cancer in HNPCC: cumulative lifetime incidence, survival and tumour distribution. A report of 121 families with proven mutations.
        Clin Genet. 2008; 74: 233-242
        • Barrow E.
        • et al.
        Cumulative lifetime incidence of extracolonic cancers in Lynch syndrome: a report of 121 families with proven mutations.
        Clin Genet. 2009; 75: 141-149
        • Ramsoekh D.
        • et al.
        Cancer risk in MLH1, MSH2 and MSH6 mutation carriers; different risk profiles may influence clinical management.
        Hered Cancer Clin Pract. 2009; 7: 17
        • Stoffel E.
        • et al.
        Calculation of risk of colorectal and endometrial cancer among patients with Lynch syndrome.
        Gastroenterology. 2009; 137: 1621-1627
        • Baglietto L.
        • et al.
        Risks of Lynch syndrome cancers for MSH6 mutation carriers.
        J Natl Cancer Inst. 2010; 102: 193-201
        • Bonadona V.
        • et al.
        Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome.
        JAMA. 2011; 305: 2304-2310
        • Therkildsen C.
        • et al.
        Cancer risks and immunohistochemical profiles linked to the Danish MLH1 Lynch syndrome founder mutation.
        Fam Cancer. 2012; 11: 579-585
        • Senter L.
        • et al.
        The clinical phenotype of Lynch syndrome due to germ-line PMS2 mutations.
        Gastroenterology. 2008; 135: 419-428
        • Pilarski R.
        Cowden syndrome: a critical review of the clinical literature.
        J Genet Couns. 2009; 18: 13-27
        • Riegert-Johnson D.
        • et al.
        Cancer and Lhermitte–Duclos disease are common in Cowden syndrome patients.
        Hered Cancer Clin Pract. 2010; 8: 6
        • Tan M.
        • Mester J.L.
        • Ngeow J.
        • Rybicki L.A.
        • Orloff M.S.
        • Eng C.
        Lifetime cancer risks in individuals with germline PTEN mutations.
        Clin Cancer Res. 2012; 18: 400-407
        • Bubien V.
        • et al.
        High cumulative risks of cancer in patients with PTEN hamartoma tumour syndrome.
        J Med Genet. 2013; 50: 255-263
        • Gonzalez K.D.
        • et al.
        Beyond Li Fraumeni syndrome: clinical characteristics of families with p53 germline mutations.
        J Clin Oncol. 2009; 27: 1250-1256
        • Hemminki A.
        • et al.
        A serine/threonine kinase gene defective in Peutz–Jeghers syndrome.
        Nature. 1998; 391 ([34]): 184-187
        • Loveday C.
        • et al.
        Germline mutations in RAD51D confer susceptibility to ovarian cancer.
        Nat Genet. 2011; 43: 879-882
        • Loveday C.
        • et al.
        Germline RAD51C mutations confer susceptibility to ovarian cancer.
        Nat Genet. 2012; 44: 475-476
        • Rafnar T.
        • et al.
        Mutations in BRIP1 confer high risk of ovarian cancer.
        Nat Genet. 2011; 43: 1104-1107
        • Casadei S.
        • et al.
        Contribution of inherited mutations in the BRCA2-interacting protein PALB2 to familial breast cancer.
        Cancer Res. 2011; 71: 2222-2229
        • Walsh T.
        • et al.
        Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing.
        Proc Natl Acad Sci. 2011; 108: 18032-18037
        • Rio Frio T.
        • et al.
        DICER1 mutations in familial multinodular goiter with and without ovarian Sertoli–Leydig cell tumors.
        JAMA. 2011; 305: 68-77
        • Sabbaghian N.
        • et al.
        Germ-line deletion in DICER1 revealed by a novel MLPA assay using synthetic oligonucleotides.
        Eur J Hum Genet. 2014; 22: 564-567
        • Kupryjańczyk J.
        • et al.
        Ovarian small cell carcinoma of hypercalcemic type — evidence of germline origin and SMARCA4 gene inactivation. a pilot study.
        Pol J Pathol. 2013; 64: 238-246
        • Jelinic P.
        • et al.
        Recurrent SMARCA4 mutations in small cell carcinoma of the ovary.
        Nat Genet. 2014; 46: 424-426
        • Witkowski L.
        • et al.
        Germline and somatic SMARCA4 mutations characterize small cell carcinoma of the ovary, hypercalcemic type.
        Nat Genet. 2014; 46: 438-443
        • Ramos P.
        • et al.
        Small cell carcinoma of the ovary, hypercalcemic type, displays frequent inactivating germline and somatic mutations in SMARCA4.
        Nat Genet. 2014; 46: 427-429
        • Kriege M.
        • et al.
        Efficacy of MRI and mammography for breast cancer screening in women with a familial or genetic predisposition.
        N Engl J Med. 2004; 351: 427-437
        • Warner E.
        • et al.
        Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination.
        JAMA. 2004; 292: 1317-1325
        • Jarvinen H.J.
        • et al.
        Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer.
        Gastroenterology. 2000; 118: 829-834
        • Phillips K.A.
        • et al.
        Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers.
        J Clin Oncol. 2013; 31: 3091-3099
        • Gronwald J.
        • et al.
        Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: An update.
        Int J Cancer. 2006; 118: 2281-2284
      1. Available from:

        • Domchek S.M.
        • et al.
        Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.
        JAMA. 2010; 304: 967-975
        • Fong P.C.
        • et al.
        Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval.
        J Clin Oncol. 2010; 28: 2512-2519
        • Couch F.J.
        • et al.
        Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk.
        PLoS Genet. 2013; 9: e1003212
        • Bellcross C.A.
        • Page P.Z.
        • Meaney-Delman D.
        Direct-to-consumer personal genome testing and cancer risk prediction.
        Cancer J. 2012; 18: 293-302
        • Weitzel J.N.
        • et al.
        Limited family structure and BRCA gene mutation status in single cases of breast cancer.
        JAMA. 2007; 297: 2587-2595
        • Kauff N.D.
        • Offit K.
        Modeling genetic risk of breast cancer.
        JAMA. 2007; 297: 2637-2639
        • Kramer J.L.
        • Velazquez I.A.
        • Chen B.E.
        • Rosenberg P.S.
        • Struewing J.P.
        • Greene M.H.
        Prophylactic oophorectomy reduces breast cancer penetrance during prospective, long-term follow-up of BRCA1 mutation carriers.
        J Clin Oncol. 2005; 23: 8629-8635
        • Lynch Syndrome
        Practice Bulletin No. 147. Society of Obstetricians and Gynecologists.
        Obstet Gynecol. 2014; 124: 1042-1054
        • Schwartz M.D.
        • et al.
        Randomized noninferiority trial of telephone versus in-person genetic counseling for hereditary breast and ovarian cancer.
        J Clin Oncol. 2014; 32: 618-626
        • Hall M.
        • Rich S.S.
        Laws restricting health insurers' use of genetic information: impact on genetic discrimination.
        Am J Hum Genet. 2000; 66: 293-307
        • Armstrong K.
        • et al.
        Life insurance and breast cancer risk assessment: adverse selection, genetic testing decisions, and discrimination.
        Am J Med Genet A. 2003; 120A: 359-364

      Linked Article